Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.72 |
| ▸ | PLAU | P00749 | 1/20 | 0.72 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | GMNN | O75496 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | THPO | P40225 | 1/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibrompropamidine SCHEMBL2471251 | 1.00 | F2 (0.72) | F2PLAUST14POLBALDH1A1 | |
| Dibrompropamidine SCHEMBL30231952 | 1.00 | F2 (0.72) | F2PLAUST14POLBALDH1A1 | |
| SCHEMBL20528835 | 0.96 | F2 (0.67) | F2PLAUST14POLBALDH1A1 | |
| SCHEMBL3006160 | 0.96 | F2 (0.67) | F2PLAUST14POLBALDH1A1 | |
| SCHEMBL985038 | 0.96 | F2 (0.67) | F2PLAUST14POLBALDH1A1 | |
| Dibrompropamidine SCHEMBL29709297 | 0.85 | F2 (1.00) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL292947 | 0.85 | F2 (1.00) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL29232796 | 0.84 | F2 (0.71) | F2PLAUST14PRSS1 | |
| Dibrompropamidine SCHEMBL21083095 | 0.84 | F2 (0.97) | F2PLAUST14PRSS1 | |
| SCHEMBL14599538 | 0.81 | F2 (0.90) | F2PLAUST14PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346910-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | COMMENSE BIO INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20230363380-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2023-11-16 | — | — | US | claimed |
| US-20220288135-A1 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS | BioPlx, Inc. (US) | 2022-09-15 | — | — | US | claimed |
| EP-3996510-A2 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS | BioPlx, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220079145-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2022-03-17 | — | — | US | claimed |
| WO-2021007341-A2 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS | BioPlx, Inc. (US) | 2021-01-14 | — | — | WO | claimed |
| US-10806741-B2 | Treatments for free-living amoebic infections | PROFOUNDA, INC. (US) | 2020-10-20 | — | — | US | claimed |
| EP-3720458-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | BioPlx, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| WO-2020068562-A1 | NOVEL TREATMENTS FOR FREE-LIVING AMOEBIC INFECTIONS | PROFOUNDA, INC. (US) | 2020-04-02 | — | — | WO | claimed |
| US-20200093842-A1 | NOVEL TREATMENTS FOR FREE-LIVING AMOEBIC INFECTIONS | PROFOUNDA, INC. (US) | 2020-03-26 | — | — | US | claimed |
| US-20190169623-A1 | METHODS AND COMPOSITIONS TO PREVENT MICROBIAL INFECTION | COMMENSE BIO, INC. | 2019-06-06 | — | — | US | claimed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | claimed |
| US-20070128121-A1 | Polymer hydrogels for controlled release and absorption of biocides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2007-06-07 | — | — | US | claimed |
| EP-0423391-B1 | Toilet bowl cleaners containing iodophors | KIWI BRANDS INC (US) | 1994-08-24 | — | — | EP | claimed |
| EP-0580627-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTRITIS | SMITHKLINE BEECHAM PLC (GB) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018111-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTRITIS | SMITHKLINE BEECHAM PLC (GB) | 1992-10-29 | — | — | WO | claimed |
| EP-0423391-A1 | Toilet bowl cleaners containing iodophors | KIWI BRANDS INC (US) | 1991-04-24 | — | — | EP | claimed |
| US-4911859-A | Polyoxyethylene oxide | KIWI BRANDS, INC. (US) | 1990-03-27 | — | — | US | claimed |
| WO-1984004456-A1 | IMPROVED COMPOSITIONS FOR TREATING INFECTED BURN WOUNDS | UNIV STRATHCLYDE (GB) | 1984-11-22 | — | — | WO | claimed |
| EP-0125858-A1 | Improved compositions for treating infected burn wounds | University of Strathclyde (GB) | 1984-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806741-B2 | Treatments for free-living amoebic infections | TUBB4B, TUBB2B, TUBB | F2 1787/4885PLAU 1823/4885ST14 2362/4885 |
| US-20070128121-A1 | Polymer hydrogels for controlled release and absorption of biocides | USP21, PHB2, BAP1 | F2 4558/4885PLAU 1487/4885ST14 256/4885 |
| US-20200093842-A1 | NOVEL TREATMENTS FOR FREE-LIVING AMOEBIC INFECTIONS | TUBB4B, CHMP4B, TUBB2B | F2 2724/4885PLAU 1843/4885ST14 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.